Abstract:The human epidermal growth factor receptor-2-positive (HER2+) type is aggressive and has poor prognosis. Although anti-HER2 therapy alone or in combination with other treatment regimens showed significant improvement in survival outcomes, breast cancer patients are still suffering from tumor relapse and severe dose -limiting side effects. Thus, there is still an unmet challenge to develop effective therapeutic agents for HER2+ breast cancer treatment with minimized side effects. Herein, we produced a stimuli-responsive and tumor -targeted hyaluronic acid (HA) nanocomplex that combined HER2 blockade and chemotherapy for effective HER2+ breast cancer therapy. A hydrophobic NIR-II dye, IR1048, was covalently linked with HA to form a spherical HA-IR1048 nanoparticle (HINP), with Herceptin conjugated on the surface and paclitaxel (PTX) encapsulated inside. The fluorescent signals from the yielding Her-HINP/PTX are quenched originally, but a strong NIR-II signal is generated when HINP is degraded by the hyaluronidase that is overexpressed in breast tumors, thus allowing the tracking and visualization of Herceptin and PTX accumulation. Her-HINP/PTX peaked in HER2+ tumors at 24 h post injection as imaged by NIR-II fluorescent imaging. A significantly improved tumor growth inhibition effect was observed after five systemic treatments compared to single PTX (3.71 +/- 0.41 times) or Herceptin (5.98 +/- 0.51 times) treatment in a HER2-overexpressed breast cancer mouse model with prolonged survival. Collectively, the designed Her-HINP/PTX presents a new hyaluronidase-responsive and HER2 blockade nanoformulation that can visualize the accumulation of nanocomplexes and release drugs inside tumors for combined HER2+ breast cancer therapy with a great promise for translational study.Statement of significance: The high expressions of a protein called human epidermal growth factor receptor 2 (HER2) in breast tumors make this subtype of cancer aggressive. Currently, chemotherapy combined with a HER2 antibody, Herceptin, is a preferred approach for HER2-positive breast cancer therapy. However, these breast cancer patients still suffer from tumor relapse and severe side effects because various therapeutic agents have inherent different biodistributions, resulting in insufficient treatment effects and unfavorable normal organ uptake of these therapeutic agents. Herein, we produced a nanocomplex carrying both Herceptin and chemo-therapy drug to simultaneously deliver two drugs into tumors for efficient HER2+ tumor treatment with mini-mized side effects, providing new insights for designing a combined therapy strategy.

Cascaded Aptamers-Governed Multistage Drug Delivery System Based on Biodegradable Envelope Type Nanovehicle for Targeted Therapy of HER2-overexpressing Breast Cancer.

A Sequentially Triggered Nanosystem for Precise Drug Delivery and Simultaneous Inhibition of Cancer Growth, Migration, and Invasion

Tumor Targeting Antibody-Conjugated Nanocarrier with Ph/thermo Dual-Responsive Macromolecular Film Layer for Enhanced Cancer Chemotherapy

A Dual-Functional Her2 Aptamer-Conjugated, Ph-Activated Mesoporous Silica Nanocarrier-Based Drug Delivery System Provides In Vitro Synergistic Cytotoxicity In Her2-Positive Breast Cancer Cells

Controllable Drug Delivery by Na+/K+ ATPase Α1 Targeting Peptide Conjugated DSPE-PEG Nanocarriers for Breast Cancer

Multifunctional Nanosystem for Targeted and Controlled Delivery of Multiple Chemotherapeutic Agents for the Treatment of Drug-Resistant Breast Cancer

Targeted gold nanoshelled hybrid nanocapsules encapsulating doxorubicin for bimodal imaging and near-infrared triggered synergistic therapy of Her2-positve breast cancer.

A Multifunctional Bimetallic Nanoplatform for Synergic Local Hyperthermia and Chemotherapy Targeting HER2-Positive Breast Cancer

Amifostine-conjugated Ph-Sensitive Calcium Phosphate-Covered Magnetic-Amphiphilic Gelatin Nanoparticles for Controlled Intracellular Dual Drug Release for Dual-Targeting in HER-2-overexpressing Breast Cancer.

Hyaluronidase-triggered Anticancer Drug and Sirna Delivery from Cascaded Targeting Nanoparticles for Drug-Resistant Breast Cancer Therapy

Targeted delivery of anticancer drugs by aptamer AS1411 mediated Pluronic F127/cyclodextrin-linked polymer composite micelles.

Copolymer Micelles Function As Ph-Responsive Nanocarriers to Enhance the Cytotoxicity of a HER2 Aptamer in HER2-positive Breast Cancer Cells.

Precision Therapy of Recurrent Breast Cancer through Targeting Different Malignant Tumor Cells with a HER2/CD44‐Targeted Hydrogel Nanobot

A Carrier-Free Dual-Drug Nanodelivery System Functionalized with Aptamer Specific Targeting HER2-overexpressing Cancer Cells.

Versatile hydrogel drug carrier loading with peptide-carbon dots conjugates for efficient targeting and synergistic suppression of breast cancer cell

“Stealth and Fully-Laden” Drug Carriers: Self-Assembled Nanogels Encapsulated with Epigallocatechin Gallate and Sirna for Drug-Resistant Breast Cancer Therapy

Hierarchical Integration of Degradable Mesoporous Silica Nanoreservoirs and Supramolecular Dendrimer Complex As a General-Purpose Tumor-Targeted Biomimetic Nanoplatform for Gene/small-Molecule Anticancer Drug Co-Delivery

Hyaluronidase Responsive Second Near-Infrared Fluorescent Nanocomplex for Combined HER2 Blockade and Chemotherapy of HER2+ Breast Cancer

Innovative tumor interstitial fluid-triggered carbon dot-docetaxel nanoassemblies for targeted drug delivery and imaging of HER2-positive breast cancer

Biomimetic Targeted Theranostic Nanoparticles for Breast Cancer Treatment

Tumor environment differentiated “nanodepot” programmed for site-specific drug shuttling and combinative therapy on metastatic cancer